Press release
PARP Inhibitors Market Boosted by R&D in Talazoparib and Veliparib for Ovarian and Pancreatic Cancer
PARP Inhibitors Market
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1169
Poly (ADP-ribose) polymerase (PARP) inhibitors represent a class of targeted therapeutics that act on a family of 17 enzymes responsible for synthesizing poly (ADP-ribose) chains. These chains are subsequently attached to specific proteins involved in the repair of single-strand DNA breaks-an essential mechanism for preserving genomic integrity following damage from ultraviolet radiation, ionizing radiation, chemotherapeutic agents, and environmental toxins.
By inhibiting PARP enzyme activity, these agents impair the cellular DNA repair process, resulting in the accumulation of DNA damage and ultimately inducing cell death, particularly in cancer cells that lack efficient alternative DNA repair pathways. The projected global increase in the elderly population-who are more prone to chronic diseases including cancer-is expected to significantly boost the demand for PARP inhibitors. Notably, the number of individuals aged 65 and above is expected to double in the coming years, further enhancing the market's growth potential.
However, despite favorable market prospects, growth may be hindered by the emergence of resistance mechanisms to PARP inhibitors and their limited therapeutic efficacy in certain patient populations. These limitations highlight the importance of sustained investment in research and development to optimize the clinical effectiveness and broaden the applicability of PARP inhibitors across various disease indications.
List of Prominent Players in the PARP Inhibitors Market:
• Johnson & Johnson Services, Inc.
• Merck KGaA
• GSK plc.
• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Artios Pharma
• Genentech, Inc.
• Karyopharm Therapeutics Inc.
• Repare Therapeutics Inc
• ONO PHARMACEUTICAL CO., LTD
• Jiangsu Hengrui Pharma Co., Ltd.
• Bristol-Myers Squibb Co
• AstraZeneca plc
• Checkpoint Therapeutics, Inc.
• Eisai Co., Ltd.
• IMPACT Therapeutics
• JEIL PHARMA CO., LTD.
• Kyowa Kirin Co., Ltd
• SyntheX
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
A major factor driving the growth of the PARP inhibitors market is the increasing global prevalence of prostate cancer. According to the World Cancer Research Fund, prostate cancer is the second most frequently diagnosed cancer in men and the fourth most common cancer worldwide. The growing adoption of Olaparib as a first-line treatment for advanced prostate cancer is expected to significantly enhance market expansion within this therapeutic area. Additionally, the rising use of PARP inhibitors in combination with other breast cancer therapies-such as chemotherapy and radiation-to address DNA damage caused by ultraviolet (UV) radiation is projected to further accelerate market growth.
Challenges:
The market is confronted with challenges stemming from heightened competition among pharmaceutical companies developing PARP inhibitors, which may lead to market saturation, reduced pricing power, and difficulties in product differentiation. Furthermore, the high costs associated with research, development, and clinical trials present substantial financial risks. These elevated investment requirements may deter new market entrants and influence pricing strategies, thereby affecting overall market dynamics and growth potential.
Regional Trends:
North America is expected to capture a significant share of the global PARP inhibitors market, supported by a strong compound annual growth rate (CAGR) over the forecast period. The integration of genomic testing into routine oncology practices-facilitated by advanced healthcare infrastructure and increased clinical awareness-has enabled more widespread identification of genetic mutations, thus promoting the use of targeted therapies such as PARP inhibitors. In Europe, the market is bolstered by collaborative initiatives between academic institutions and pharmaceutical companies. These strategic partnerships aim to expedite clinical research, broaden treatment indications, and enhance the therapeutic application of PARP inhibitors across various cancer types.
Recent Developments:
• In 2023, an acquisition of CinCor Pharma, Inc. was announced by AstraZeneca in order to enhance its cardiorenal pipeline. CinCor's candidate medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI), is being integrated into this strategic approach to address resistant to treatment hypertension by reducing blood pressure.
• In 2022, AstraZeneca and G42 Healthcare have formed a strategic partnership to produce pharmaceutical products in Abu Dhabi. The objective of this partnership is to improve the local manufacturing capabilities and facilitate the production of essential pharmaceuticals, thereby increasing the accessibility of healthcare in the region.
• In 2022, Helio Genomics, in collaboration with Fulgent Genetics, has obtained a new Category I CPT code from the AMA for HelioLiver, thereby facilitating the widespread implementation of advanced surveillance tests for liver cancer in the United States. This accomplishment broadens the company's market presence and product line.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1169
Segmentation of PARP Inhibitors Market-
By Product-
• Niraparib (Zejula)
• Olaparib (Lynparza)
• Rucaparib (Rubraca)
• Talazoparib (Talzenna)
• Veliparib
• Other Pipeline Drugs
By Indication-
• Ovarian Cancer
• Breast cancer
• Prostate and Pancreatic Cancer
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/global-parp-inhibitors-market-/1169
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PARP Inhibitors Market Boosted by R&D in Talazoparib and Veliparib for Ovarian and Pancreatic Cancer here
News-ID: 4100625 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Low & No Alcohol Beverages Market to Hit $46.5 Billion by 2034 With 6.2% CAGR Gr …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Low & No Alcohol Beverages Market- by Product Type (Beer (No-alcohol: 0.0- 0.5% ABV and Low-alcohol: >0.5-3.5% ABV), Still and Sparkling Wine (No-alcohol: 0.0 - 0.5% ABV and Low-alcohol: >0.5-7.5% ABV), Mixed Drinks (No-alcohol: 0.0 - 0.5% ABV and Low-alcohol: >0.5- 3% ABV), Spirits (Liqueurs)( No-alcohol: 0.0 - 0.5% ABV and Low-alcohol: >0.5- 10% ABV),…
Adalimumab Biosimilar Market to Witness Strong Growth Driven by Autoimmune Disea …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adalimumab Biosimilar Market- by Application (Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Crohn's Disease, Ankylosing Spondylitis, Ulcerative Colitis, and Psoriasis), Distribution Channel (Hospital Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
Global Adalimumab Biosimilar Market Size is estimated to grow at the CAGR of 23.0% during the…
Next-Generation Personalized Nutrition Market Expands on Back of Wearables and G …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Next-Generation Personalized Nutrition Market- by Service (Questionnaire/Survey Based, Wearables and Apps, Home Test Kits, and Others (Consultation, etc.)), Application (Biomarkers/ Diagnostic and Monitoring Tools, Genetics/ Nutrigenomics, Microbiome/Next Generation Probiotics, and Physical Traits & Lifestyle Based Solution), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the global Next-Generation…
Animal Microbiome Market Set to Hit USD 19.2 Bn by 2034, Driven by 10.6% CAGR
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Animal Microbiome Market- by Products (Phage Therapy Product, Functional Food (Probiotics, Prebiotics and Others), Sequencing Platforms, Feed Additives/Functional Ingredients, Alternative Proteins and Alternative Feed, and Other Innovative Microbiome Products and Therapies), Application (Disease Therapeutics, Diagnostics, and Nutrition), Animal Type (Poultry, Ruminants, Swine, Aquaculture, and Pets), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to…
More Releases for PARP
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction
A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market 10-Year Forecast and Trends Analysis Research Report
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market Analysis, Size, Trends and Forecasts (2016-2020)
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as it is the…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
